• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Med . Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection

tetano

Editor, Senior Moderator
Nat Med


. 2020 Aug 3.
doi: 10.1038/s41591-020-1021-2. Online ahead of print.
Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection


Vijendra Ramlall[SUP] 1 2 [/SUP], Phyllis M Thangaraj[SUP] 1 3 [/SUP], Cem Meydan[SUP] 4 5 [/SUP], Jonathan Foox[SUP] 4 6 [/SUP], Daniel Butler[SUP] 4 6 [/SUP], Jacob Kim[SUP] 7 [/SUP], Ben May[SUP] 5 [/SUP], Jessica K De Freitas[SUP] 8 9 [/SUP], Benjamin S Glicksberg[SUP] 8 9 [/SUP], Christopher E Mason[SUP] 4 6 10 11 [/SUP], Nicholas P Tatonetti[SUP] 12 13 [/SUP], Sagi D Shapira[SUP] 14 [/SUP]



Affiliations

Abstract

Understanding the pathophysiology of SARS-CoV-2 infection is critical for therapeutic and public health strategies. Viral-host interactions can guide discovery of disease regulators, and protein structure function analysis points to several immune pathways, including complement and coagulation, as targets of coronaviruses. To determine whether conditions associated with dysregulated complement or coagulation systems impact disease, we performed a retrospective observational study and found that history of macular degeneration (a proxy for complement-activation disorders) and history of coagulation disorders (thrombocytopenia, thrombosis and hemorrhage) are risk factors for SARS-CoV-2-associated morbidity and mortality-effects that are independent of age, sex or history of smoking. Transcriptional profiling of nasopharyngeal swabs demonstrated that in addition to type-I interferon and interleukin-6-dependent inflammatory responses, infection results in robust engagement of the complement and coagulation pathways. Finally, in a candidate-driven genetic association study of severe SARS-CoV-2 disease, we identified putative complement and coagulation-associated loci including missense, eQTL and sQTL variants of critical complement and coagulation regulators. In addition to providing evidence that complement function modulates SARS-CoV-2 infection outcome, the data point to putative transcriptional genetic markers of susceptibility. The results highlight the value of using a multimodal analytical approach to reveal determinants and predictors of immunity, susceptibility and clinical outcome associated with infection.
 
Back
Top Bottom